What is GRI Bio Earnings Power Value (EPV)?
As of Mar24, GRI Bio's earnings power value is $1.23. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
GRI Bio Earnings Power Value (EPV) Historical Data
The historical data trend for GRI Bio's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio Earnings Power Value (EPV) Chart
|
GRI Bio Annual Data
|
|
Trend |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
|
GRI Bio Quarterly Data
|
|
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of GRI Bio's Earnings Power Value (EPV)
For the Biotechnology subindustry, GRI Bio's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where GRI Bio's Earnings Power Value (EPV) falls into.
GRI Bio Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
GRI Bio (GRI Bio) Business Description
Traded in Other Exchanges
N/A
Address
2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Executives
| David Leslie Szekeres |
director |
C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121 |
| Roelof Rongen |
director |
C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
| Camilla V Simpson |
director |
20 ELAINE AVE., MILL VALLEY CA 94941 |
| Albert Agro |
officer: Chief Medical Officer |
828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9 |
| Walter Marc Hertz |
director, 10 percent owner, officer: Chief Executive Officer |
2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037 |
| Vipin Chaturvedi |
officer: Chief Scientific Officer |
2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037 |
| Meenu Chhabra |
director |
C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Joseph E Payne |
director |
10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
| Leanne M. Kelly |
officer: Chief Financial Officer |
C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Marella Thorell |
director |
1226 CHARTER LANE, AMBLER PA 19002 |
| Arcturus Therapeutics Holdings Inc. |
10 percent owner |
10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121 |
| Penny Toren |
officer: SVP, Regul Affairs & Prog Mgmt |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Ofir Levi |
director |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Richard Ammer |
director, 10 percent owner |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Pharma Gmbh Salmon |
10 percent owner |
SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052 |
GRI Bio (GRI Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRI has been successfully added to your